Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioLargo Inc (BLGO)
OTHER OTC:BLGO
BLGO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.16 - $0.45
Previous CloseN/A
Volume222.28K
Average Volume (3M)250.01K
Market Cap
$76.41M
Enterprise Value$65.35M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.36
Next Earnings
Mar 27, 2025Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding301,179,170
10 Day Avg. Volume205,033
30 Day Avg. Volume250,010
Standard Deviation0.20
R-Squared0.00394
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.13
Price to Cash Flow (P/CF)-11.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.62
Enterprise Value/Ebitda-19.53
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
BioLargo News
PremiumCompany Announcements
BioLargo Shares Strategic Updates in Investor Webcast
PremiumPre-Earnings
Is BLGO a Buy, Before Earnings?
PremiumCompany Announcements
BioLargo Presents Corporate Update in Investor Webcast
---
Ownership Overview
9.96% Insiders
―
Mutual Funds
0.04% Other Institutional Investors
90.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BLGO FAQ
What was BioLargo Inc’s price range in the past 12 months?
BioLargo Inc lowest stock price was $0.16 and its highest was $0.45 in the past 12 months.
What is BioLargo Inc’s market cap?
BioLargo Inc’s market cap is $76.41M.
When is BioLargo Inc’s upcoming earnings report date?
BioLargo Inc’s upcoming earnings report date is Mar 27, 2025 which is in 34 days.
How were BioLargo Inc’s earnings last quarter?
BioLargo Inc released its earnings results on Nov 14, 2024. The company reported -$0.002 earnings per share for the quarter, missing the consensus estimate of $0 by -$0.002.
Is BioLargo Inc overvalued?
According to Wall Street analysts BioLargo Inc’s price is currently Overvalued.
Does BioLargo Inc pay dividends?
BioLargo Inc does not currently pay dividends.
What is BioLargo Inc’s EPS estimate?
BioLargo Inc’s EPS estimate is 0.
How many shares outstanding does BioLargo Inc have?
BioLargo Inc has 301,179,170 shares outstanding.
What happened to BioLargo Inc’s price movement after its last earnings report?
BioLargo Inc reported an EPS of -$0.002 in its last earnings report, missing expectations of $0. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioLargo Inc?
Currently, no hedge funds are holding shares in BLGO
---
BioLargo Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.93%
12-Months-Change
Fundamentals
Return on Equity
-27.06%
Trailing 12-Months
Asset Growth
57.45%
Trailing 12-Months
Company Description
BioLargo Inc
BioLargo, Inc. engages in the provision of technology solutions for odor and moisture control, disinfection, and water treatment. It operates through the following segments: Odor-No-More and BLEST, Clyra, and Biolargo. The Odor-No-More and BLEST segment generates cash by selling products and services. The Clyra Medical obtains cash from third party investments of sales of its common stock. The BioLargo Water generates cash through government research grants and tax credits. The company was founded in 1989 and is headquartered in Westminster, CA.
---
BLGO Company Deck
---
BLGO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments and challenges. Significant growth in revenue and strong financial positioning were highlighted alongside successful partnerships and potential in new technology markets. However, the call also acknowledged some setbacks, including delayed launches and slow market adoption.Read More>---
Technical Analysis
CDTi Advanced Materials
―
Perma-Fix
―
ClearSign Combustion
―
Summit Therapeutics
―
Optinose
―
---